Over 80% of patients with advanced breast and prostate cancer ultimately develop bone metastases. Ibandronic acid has proven efficacy for treatment of bone metastasis secondary to breast cancer. This study was designed to investigate the cytotoxic and apoptotic effects of ibandronic acid on hormone-and drugrefractory prostate carcinoma DU-145 and human breast cancer MCF-7 cell lines. Cytotoxicity was evaluated using an XTT cell proliferation kit, and apoptosis was assessed by enzyme-linked immuno sorbent assay (histone-DNA fragmentation) and measurement of caspase 3/7 activity. With increasing concentrations of ibandronic acid there was a dose-and time-dependent decrease in cell numbers. MCF-7 cells were more resistant than DU-145 cells (half maximal inhibitory concentrations of 122 and 90 µM, respectively). Ibandronic acid induced apoptosis in both cell lines. The study showed an apoptosis-mediated cytotoxic effect for ibandronic acid (in addition to the already known osteoclast inhibiting effect) in breast cancer patients with bone metastases; which was also observed in prostate cancer cells. Further clinical studies involving breast and prostate cancer patients with bone metastases are warranted to confirm these findings.
Introduction
With the exception of non-melanoma skin cancer, the most commonly occurring cancers in men and women are prostate and breast cancer, respectively. 1 Once hormonerefractory disease develops, treatment options are limited and prognosis is poor.
Considering the adverse effect profiles of the chemotherapy protocols used for refractory disease, it is clear that new therapeutic options are necessary. 2, 3 Breast cancer is the second major cause of death from cancer in women, exceeded only by lung cancer. 1 Despite significant therapeutic advances, Y Kucukzeybek, G Gorumlu, E Cengız et al.
Ibandronic acid and cytotoxicity cure is unlikely in advanced disease. 1, 4 Bone metastases develop in approximately 80% of patients with advanced breast or prostate cancer, with significant consequences, including pain, movement limitations, spinal cord compression and hypercalcaemia. 5, 6 Ibandronic acid is a nitrogencontaining bisphosphonate that has proven efficacy in the treatment of bone metastasis secondary to breast cancer. Although ibandronic acid has been shown to possess some antiproliferative activity in breast cancer, it is currently not used as an antitumoural agent. 7 -13 Another widely used bisphosphonate, zoledronic acid, has also been shown to have cytotoxic properties in prostate cancer cells. 14, 15 Despite these observations, to our knowledge, there are no studies specifically addressing the cytotoxic effect of ibandronic acid in prostate cancer cells. Thus, the present study was designed to examine the cytotoxic and apoptotic effects of ibandronic acid in breast and prostate cancer cell lines.
Materials and methods

CELL LINES AND REAGENTS
Human DU-145 prostate and MCF-7 breast cancer cells were obtained from the Interlab Cell Line Collection of the National Institute for Cancer Research of Genoa, Italy. The cells were grown as adherent cell monolayers and were routinely cultured in RPMI 1640 growth media containing 10% heat-inactivated fetal bovine serum (FBS), 1% L-glutamine and 1% penicillin-streptomycin, in 75 cm 2 polystyrene flasks (Corning Life Sciences, Lowell, MA, USA). The flasks were maintained at 37°C in a humidified atmosphere with 5% carbon dioxide. Cell growth and morphology were monitored and the cells were passaged when they reached 90% confluence. Cell culture supplies were obtained from Biological Industries (Kibbutz Beit Haemek, Israel). Ibandronic acid was a generous gift from Roche (Basel, Switzerland). The stock solution of ibandronic acid (10 mM) was prepared in distilled water. The final dilutions were made immediately before use and new stock solutions were prepared for each experiment. All other chemicals, unless otherwise specified, were purchased from Sigma-Aldrich (St Louis, MO, USA).
VIABILITY ASSAY
After verifying cell viability using a trypan blue dye exclusion test and a Cellometer ® Auto automatic cell counter (Nexcelom Inc., Lawrence, MA, USA), the cells were seeded into 96-well flat-bottom microtitre plates at approximately 1 × 10 4 cells/well in a final volume of 200 µl with or without ibandronic acid (0, 10, 20, 40, 80, 100, 120 and 160 µM). The plates were incubated at 37°C in a 5% carbon dioxide atmosphere for 24, 48 or 72 h. At the end of incubation, 100 µl of XTT reagent from the Cell Proliferation Kit II (Roche Applied Science, Mannheim, Germany) was added to each well and the plates were incubated at 37°C for a further 4 h. Absorbance was measured at 450 nm against a reference wavelength of 650 nm using a microplate reader (DTX 880 Multimode Reader; Beckman Coulter Inc., Brea, CA, USA). All conditions were repeated in triplicate in at least two independent experiments and the mean values for each dose were used to calculate the half maximal inhibitory concentration (IC 50 ).
EVALUATION OF APOPTOSIS
Apoptosis was evaluated by enzyme-linked immunosorbent assay (ELISA) using the Cell Death Detection ELISA Plus Kit (Roche Applied Science) according to the instruction manual. The relative amounts of mono-and oligonucleosomes generated from the apoptotic cells were quantified using Y Kucukzeybek, G Gorumlu, E Cengız et al.
Ibandronic acid and cytotoxicity monoclonal antibodies directed against DNA and histones by ELISA. Briefly, the cytoplasmic fractions of the untreated control cells and cells that were treated with ibandronic acid, at IC 50 concentrations, for 72 h were transferred onto a streptavidincoated 96-well plate and incubated for 2 h at room temperature with a mixture of peroxidase conjugated anti-DNA and biotin-labelled antihistone. The plate was washed thoroughly, incubated with 2,2′azino-di-(3-ethylbenzthiazoline sulphonate) diammonium salt and absorbance was measured at 405 nm with a reference wavelength of 490 nm (DTX 880 Multimode Reader). All conditions were repeated in triplicate in at least two independent experiments and the mean values were calculated.
MEASUREMENT OF CASPASE 3/7 ENZYME ACTIVITY
Apoptosis was also confirmed using the Caspase-Glo ® 3/7 assay (Promega, Madison, WI, USA) as described by the manufacturer. Briefly, DU-145 and MCF-7 cells at a concentration of 10 4 cells/well were plated into 96-well plates in 100 µl of culture medium in the absence or presence of ibandronic acid, at IC 50 concentrations, for 72 h. Then, 100 µl of Caspase-Glo ® 3/7 reagent was added to each well and the plates were incubated at room temperature for a further 1 h. 
STATISTICAL ANALYSIS
Data were analysed by using GraphPad PRISM 5.0 software (San Diego, CA, USA). All conditions were repeated in triplicate in at least two independent experiments and the final value was expressed as the ratio of expression (y-axis) ± SD. Data were analysed using Student's t-test to compare results between two groups. Dose-and timedependent effects were determined using two-way analysis of variance. A P-value < 0.05 was considered to be statistically significant.
Results
CELL GROWTH
The percentage viability of DU-145 and MCF-7 cells exposed to ibandronic acid at a range of doses from 10 to 160 µM for periods of 24, 48 and 72 h are shown in Fig 
DETECTION OF APOPTOSIS
The induction of apoptosis in DU-145 and MCF-7 cells, exposed to ibandronic acid at IC 50 concentrations for 72 h, was assessed by ELISA to detect fragmentation of DNA and by measurement of caspase 3/7 enzyme Y Kucukzeybek, G Gorumlu, E Cengız et al.
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activity and results are shown in Figs 5 and 6, respectively. Compared with positive controls, there was a significant increase in caspase 3/7 enzyme activity and DNA fragmentation in both the DU-145 and MCF-7 cells in response to IC 50 concentrations of ibandronic acid (P < 0.05). DU-145 cells exposed to 90 µM ibandronic acid and MCF-7 cells exposed to 122 µM ibandronic acid showed a 1.9 and 2.5-fold increase in DNA fragmentation, respectively (Fig. 5) , and a 1.8 and 2.0-fold increase in caspase 3/7 enzyme activity respectively (Fig. 6 ), compared to untreated controls. Thus, apoptosis-mediated cytotoxicity was demonstrated for both cell lines. 
Discussion
Bone metastases develop in almost 80% of patients with advanced breast or prostate cancer. 5 Ibandronic acid is a nitrogencontaining bisphosphonate with proven efficacy in the treatment of breast cancer. Although some studies have examined the effect of ibandronic acid in breast or prostate cancer cell lines, a direct cytotoxic effect of ibandronic acid on prostate cancer cells has not, to our knowledge, been shown previously. The cytotoxic and apoptotic effects of ibandronic acid on DU-145 prostate cancer cells and MCF-7 breast cancer cells were evaluated in the present study. A cytotoxic 13 have shown previously that the cytotoxic effect of ibandronic acid on breast cancer cell lines is mediated by apoptosis and this effect persisted for up to 6 days of culture. The cytotoxic effect of ibandronic acid in the present study was time-and dose-dependent at all concentrations tested, with a decrease in the proliferative activity of MCF-7 breast cancer cells by 20%, 30% and 52% at 24, 48 and 72h, respectively, at the highest concentration tested (160 µM). Hiraga et al. 16 administered ibandronic acid to mice following the development of bone metastases and observed a decrease in tumour burden as well as induction of apoptosis in breast cancer cells causing bone metastasis. In their study, an apoptotic effect was absent at 1 and 10 µM ibandronic acid but present at 100 µM. The IC 50 concentration for MCF-7 breast cancer cells obtained in the present study is in agreement with the results of Hiraga et al. 16 Boissier et al. 17, 18 found some evidence suggesting that ibandronic acid is not only effective for established bone metastases, but also in cases with a high likelihood of development of bone metastasis. They found docetaxel chemotherapy has some serious side effects for most patients with hormonerefractory prostate cancer 21 -23 and, therefore, it is clear that novel therapeutic strategies are needed.
Combined with data from the published literature, the present study provides some preliminary evidence for the positive prognostic effect of ibandronic acid in patients with advanced prostate cancer, similar to that in patients with breast cancer. Further clinical studies are warranted to clarify whether the addition of ibandronic acid to existing treatment protocols for breast or prostate cancer will prove to be a novel and effective strategy.
